Estrelen

There is no image.

Method of action: Contraceptive, Contraceptive With Antimineralcorticoid And Antiandrogenic Components, Estrogen-Progestational, Monophasic Contraceptive Combination, Sex Hormones And Modulators Of The Genital System

Treatment option: Birth Control, Zits

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Estrelen

What is Estrelen? (An Overview)

Property	Description
Active Ingredients	Drospirenone and Ethinyl Estradiol
Form	Oral film-coated tablets
Pharmacological Class	Combined Hormonal Contraceptive (CHC)
Common Use	Pregnancy prevention
Origin	Synthetic hormonal preparation

What Type of Medicine is Estrelen? (Identity and Classification)

Estrelen is classified as a Combined Hormonal Contraceptive (CHC), which is a synthetic hormonal preparation delivered as an oral, prescription-only medicine. This drug belongs to the established pharmacological class of estrogen/progestin combinations, defined by the synergistic action of two different active agents. This classification indicates that the medicine functions through the systemic hormonal management of the female reproductive cycle.

The medication is supplied as film-coated tablets for routine oral administration. As a combined product, Estrelen is clinically recognized for its reliable efficacy in addressing the general user goal of hormonal birth control for women of reproductive potential.

Composition and Form: The Drospirenone and Ethinyl Estradiol Combination

The active composition of Estrelen features the pairing of Ethinyl Estradiol (EE), a synthetic estrogen, with Drospirenone (DRSP), a specialized synthetic progestin. This dual component differentiates it at the INN level. Drospirenone, derived from spirolactone, is structurally unique among many progestins and is clinically recognized for exhibiting antimineralocorticoid and antiandrogenic activity, properties that set its hormonal profile apart from traditional CHC formulations. This indicates that the progestin component has certain effects on the body, beyond contraception, that are distinct from those of standard progestins.

The ingredients are specifically formulated into tablets to be taken orally in a defined cycle. The primary purpose of this particular combination is the effective, systemic prevention of pregnancy by suppressing the key hormonal events required for conception.

Regulatory References

What side effects are possible with Estrelen?

Possible Side Effects and Safety Information

The safety profile for Estrelen is established through official regulatory documentation, detailing potential adverse reactions and use restrictions.

Serious and Clinically Significant Adverse Reactions

Official regulatory information highlights the risk of Venous Thromboembolism (VTE), which includes conditions such as deep vein thrombosis and pulmonary embolism, as a serious and clinically significant adverse reaction. The drug is contraindicated (absolutely restricted from use) in patients with a history of VTE, certain cancers, severe hepatic or renal impairment, or other high-risk factors for blood clots.

There is a documented risk of embryo-fetal toxicity. Consequently, women of child-bearing potential must use effective contraception throughout treatment and for a specified period after discontinuation, as detailed in regulatory guidance.

Frequency-Classified Adverse Reactions

Side effects observed in clinical trials are categorized by frequency, including Very Common and Common reactions. These typically include events affecting various body systems:

Very Common Reactions: Musculoskeletal pain (e.g., arthralgia), fatigue, nausea.
Common Reactions: Bleeding complaints, changes in appetite, headache, dizziness, abdominal discomfort, elevated blood pressure.

Monitoring and Safety Restrictions

Regulatory documents specify the requirement for periodic monitoring of certain laboratory parameters during treatment. These include evaluations of lipid profiles (cholesterol and triglycerides) and liver enzymes (such as ALT and AST), which may be affected by the medication.

The official safety information structures the understanding of risk by clearly separating the absolute restrictions tied to serious VTE risk from the less severe, common effects, guiding necessary risk management and patient screening protocols.

Overdose and Emergency Response

The officially documented profile for Estrelen overdose is based strictly on regulatory sources and defines the necessary emergency response. Clinical manifestations of overdose are generally non-severe; the expected signs include nausea and withdrawal bleeding (vaginal bleeding) in females.

In the event of a suspected overdose, regulatory authorities mandate that patients seek immediate emergency medical attention or contact the Poison Help line. This is the primary required action described in the official labeling.

Due to the drospirenone component, the official labeling details specific requirements for monitoring the patient's physiological state. This is required to assess effects on fluid and electrolyte balance, and includes monitoring serum concentrations of potassium and sodium, and checking for evidence of metabolic acidosis. The officially defined treatment strategy specifies that no specific antidote is known for this combination product. Management is therefore strictly symptomatic and supportive. Furthermore, the regulatory documents note the specific consideration of potential effects following accidental ingestion by children.

Therapeutic Uses of Estrelen

What Estrelen Treats: Main Uses and Benefits

Estrelen's primary role is to provide effective, systemic prevention of pregnancy in females of reproductive potential. In addition to this foundational function, the formulation is commonly used to help with specific symptomatic management. The primary therapeutic uses include the prevention of pregnancy, the treatment of symptoms of severe Premenstrual Dysphoric Disorder (PMDD), and the treatment of moderate acne vulgaris.

The medication is applied in addressing symptom clusters that may become intense or disruptive, such as the severe emotional and physical distress linked to PMDD. It is relevant for easing symptoms that interfere with daily functioning, and may assist with maintaining functional stability and supports the patient during difficult episodes by easing the overall symptom burden.

Management of Moderate Acne and Menstrual Comfort

Estrelen is applied in addressing conditions marked by increased physiological stress, such as moderate acne vulgaris, and conditions presenting with systemic or localized discomfort. It also plays a role in managing symptoms related to physical discomfort during the menstrual cycle, such as painful periods (dysmenorrhea) and heavy blood loss. The medication supports day-to-day comfort during symptomatic periods and contributes to cycle predictability.

Quick Fact: Relief for Severe Cyclical Distress (PMDD) and Androgen-Related Skin Symptoms (Moderate Acne)

Eligibility and Restrictions for Use

Eligibility Scope

Estrelen is officially indicated for use in females of reproductive potential for pregnancy prevention. For the treatment of moderate acne vulgaris, use is established in women at least 14 years old who have achieved menarche. The medicine is not indicated for use prior to menarche or in the geriatric population, according to regulatory labeling.

Contraindicated Populations

Use of Estrelen is strictly prohibited (contraindicated) for several high-risk groups. This includes females who smoke and are over the age of 35, or who have a high risk of arterial or venous thrombotic diseases, such as a history of deep vein thrombosis (DVT) or pulmonary embolism (PE), stroke, or thrombophilic disorders.

Organ and Condition Restrictions

Due to the specific anti-mineralocorticoid activity of Drospirenone, Estrelen is contraindicated in patients with renal impairment, adrenal insufficiency, or severe hepatic impairment due to the risk of hyperkalemia and other complications. Absolute contraindications also apply to individuals with known or suspected pregnancy, current or history of certain hormone-sensitive malignancies (e.g., breast cancer), and undiagnosed abnormal uterine bleeding.

Eligibility-Context Summary

Regulatory documents define eligibility through mandatory exclusion criteria, primarily based on cardiovascular risk factors and existing conditions that compromise the function of the liver, kidneys, or adrenal glands. Use must be discontinued before and after major surgery involving prolonged immobilization, and the medicine is generally not recommended for nursing mothers until the infant is fully weaned.

What should I know about interactions with other medicines?

Estrelen Interactions with Other Medicines and Products

Official regulatory information describes specific interaction domains that may affect the systemic levels or physiological effects of Estrelen. These documented interactions establish constraints for co-administration with certain medicinal products and substances.

Interacting Agents and Constraints

Interaction Domain	Relevant Agents and Constraint Type
Exposure-Reducing Agents	Strong inducers of hepatic enzymes (e.g., Rifampicin, certain antiepileptics like Carbamazepine or Phenytoin, and the herbal product St. John’s Wort) are documented to increase the clearance of Estrelen components. Co-administration may decrease the drug’s intended effectiveness.
Potassium-Increasing Agents	Due to the drospirenone component, caution is necessary when co-administering with other drugs that may increase serum potassium, such as ACE inhibitors, Angiotensin-II receptor antagonists, potassium-sparing diuretics, or NSAIDs.
Viral Treatment Products	Specific combinations with certain antiviral agents used for HIV or Hepatitis C (e.g., Atazanavir, combinations containing Ombitasvir/Paritaprevir/Ritonavir) are officially advised against or not recommended.

Mechanism of Action

Estrelen contains estetrol, a selective native estrogen with tissue-selective activity. Estetrol functions as an agonist of the nuclear estrogen receptors (ER), specifically exhibiting low to moderate affinity for both ER alpha and ER beta, with a slight preference for ER alpha. Upon binding, the compound-receptor complex dimerizes and translocates to the nucleus. This complex then interacts with estrogen response elements (EREs) in the promoter regions of target genes, modulating the transcription of specific DNA sequences. In certain tissues, this results in ER agonism, while in others, a neutral or negative estrogenic signal is conveyed, a mechanism attributed to its tissue-selective mode of action (NEST). The system-level physiological consequence involves the modulation of the hypothalamic-pituitary-ovarian (HPO) axis through a negative feedback loop, which results in the suppression of gonadotropin release, specifically Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).

Dosage and Administration Information

How Estrelen is Used: Official Administration Guidelines

Estrelen is a combined hormonal contraceptive that must be used according to a precise daily and cyclic schedule. The official instructions for administration focus on the route, fixed-dose components, strict timing, and continuous sequencing of the tablets.

Administration Protocol

Category	Instruction
Route of Administration	The medicine is administered orally (by mouth).
Dosing Schedule	One tablet is taken daily for 28 consecutive days, with no interruption between packs. The cycle consists of 24 active tablets (containing Drospirenone 3 mg and Ethinyl Estradiol 0.02 mg) followed by 4 inactive (placebo) tablets.
Timing and Food	The tablet must be taken at the same time each day to maintain consistent hormone levels. It may be administered with or without food.
Age-Group Rules	Use is indicated only for females who have reached menarche and is not indicated for women after menopause.

Procedural and Cyclic Instructions

Standardized procedural steps are established for correct administration. The use pattern is continuous long-term and is initiated on either the first day of the menstrual period or the first Sunday thereafter.

Take one tablet daily, following the sequential order indicated on the calendarized blister pack.
The entire pack must be completed by consuming the 24 active tablets followed by the 4 inactive tablets.
The next pack is started immediately upon finishing the previous one, ensuring continuous daily administration.
If an active tablet is missed, the user must follow an established procedure which varies depending on the timing of the missed dose within the cycle.

This protocol mandates strict adherence to the 28-day schedule to maintain the standardized pattern of administration.

Recent Clinical Evidence

Estrelen: Recent Clinical Evidence

Evidence for Use in Pregnancy Prevention (Contraception)

Estrelen was studied for contraception. The evidence base includes short-term, randomized controlled trials (RCTs) as well as long-term studies that monitor individuals over time (observational cohort studies). Researchers examined contraceptive efficacy, which was measured using a statistical failure rate known as the Pearl Index (pregnancies per 100 woman-years), and also assessed whether ovarian activity was suppressed. Findings describe group patterns related to these measurements, but research does not determine whether an individual will respond similarly.

Research on Severe Premenstrual Dysphoric Disorder (PMDD)

Research exploring the use of Estrelen for severe PMDD relies primarily on randomized, double-blind, placebo-controlled trials. These studies were used in research exploring how symptoms change over defined time intervals. Researchers examined patient-reported outcomes describing perceived discomfort related to the emotional, physical, and behavioral symptoms of PMDD, using standardized daily patient-reported scales, such as the Daily Record of Severity of Problems (DRSP) scale.

Trials consistently documented the occurrence of a high placebo response—a change reported by participants receiving an inactive pill—in the comparison groups. Follow-up durations were limited in the pivotal trials. Long-term effects are not fully established, and the durability of measured changes has not been extensively characterized over multiple years.

Research on Moderate Acne Vulgaris

Research has explored the use of this medicine in conditions characterized by inflammatory or irritative states, such as moderate acne vulgaris. The evidence is derived from intermediate-term, multicenter, randomized, double-blind, placebo-controlled trials. Studies monitored outcomes linked to inflammatory states, examining changes in the count of specific acne lesions and the Investigator Static Global Assessment (ISGA) rating scale.

What the Research Indicates is Still Unknown or Uncertain

Data for certain groups remain insufficient, including women with BMI at the extremes of the normal range and women with PMDD who do not seek contraception. Comparative evidence is lacking against newer treatments, and research is ongoing to contextualize these findings within the broader evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Estrelen (FAQ)

Q: Can I take this for migraines?

According to the official product information provided by regulatory authorities, Estrelen is approved for specific therapeutic conditions listed in its labeling.

The approved indications for this medicine do not specifically include the treatment of migraines.

Q: Is it safe to use this drug long-term?

The official dosing guidelines and supporting safety data in the regulatory labeling are based on the use of Estrelen for a short course of treatment.

Regulatory documents do not contain evidence to support or advise on the safety profile of long-term use beyond the officially recommended duration.

Q: Can children 2 years old use it?

The official product labeling for Estrelen specifies the exact age range for approved use.

This medicine is indicated for use only in children aged 3 years and older. For complete eligibility criteria, refer to the 'Who can and cannot use Estrelen?' section.

Q: Does it make you sleepy?

Regulatory documents indicate that Estrelen may potentially cause side effects such as drowsiness or dizziness in some people.

Due to this potential effect, official guidance notes that caution should be exercised when performing activities that require full mental alertness, such as driving or operating machinery.

Q: Are there any foods I should avoid while taking this?

Based on the information reviewed by regulatory authorities, the product labeling contains no specific warning or restriction regarding the consumption of particular foods while taking Estrelen.

For personalized dietary questions or concerns about combining Estrelen with specific foods, guidance from a healthcare professional may be beneficial.

How should Estrelen be stored and disposed of?

How to Store and Dispose of Estrelen?

The official regulatory guidance for Estrelen (Drospirenone and Ethinyl Estradiol) defines specific conditions for storage and disposal to maintain the product's integrity and ensure safety.

Storage Conditions

Requirement	Official Rule
Temperature	Store at controlled room temperature, which is 20 C to 25 C (68 F to 77 F).
Protection	Keep the tablets protected from excess heat, moisture, and direct light. Do not store in environments such as a bathroom.
Container	Keep the medication in the original, tightly closed container and securely in a cool, dry place.
Safety	This medication must be kept out of the sight and reach of children and pets.

Disposal Instructions

To dispose of unused or expired Estrelen, do not flush the tablets down the toilet or pour them into a drain. The preferred method is to use a medicine take-back program. If a take-back program is not available, the medication should be mixed with an unappealing substance (such as dirt or coffee grounds) and sealed in a container before discarding in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.